Advances in new antivirals for chronic hepatitis B / 中华医学杂志(英文版)
Chinese Medical Journal
; (24): 571-583, 2022.
Artigo
em Inglês
| WPRIM (Pacífico Ocidental)
| ID: wpr-927536
Biblioteca responsável:
WPRO
ABSTRACT
Chronic hepatitis B virus (HBV) infection remains a global health burden. Timely and effective antiviral therapy is beneficial for patients with HBV infection. With existing antiviral drugs, including nucleos(t)ide analogs and interferon-alfa, patients can achieve viral suppression with improved prognosis. However, the rate of hepatitis B surface antigen loss is low. To achieve a functional cure and even complete cure in chronic hepatitis B patients, new antivirals need to be developed. In this review, we summarized the advantages and disadvantages of existing antiviral drugs and focused on new antivirals including direct-acting antiviral drugs and immunotherapeutic approaches.
Texto completo:
Disponível
Contexto em Saúde:
ODS3 - Saúde e Bem-Estar
Problema de saúde:
Meta 3.8 Atingir a cobertura universal de saúde
Base de dados:
WPRIM (Pacífico Ocidental)
Assunto principal:
Antivirais
/
Vírus da Hepatite B
/
Hepatite B Crônica
/
Hepatite C Crônica
/
Hepatite B
/
Antígenos de Superfície da Hepatite B
Limite:
Humanos
Idioma:
Inglês
Revista:
Chinese Medical Journal
Ano de publicação:
2022
Tipo de documento:
Artigo